Novo Nordisk A/S (NVO) — closed signal from September 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 10, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published September 11, 2025
Shares fell after headlines about a lawsuit and a possible corporate change, but an independent reviewer said Wegovy and Zepbound are worth the cost, which supports long-term value. The drop looks overdone and early signs suggest buyers may be returning. If the price climbs back above 56-57, we expect a rebound over the next 0-3 months. We will start small and add once the move is confirmed to manage legal and budget risks.
Primary drivers
- Leader in weight-loss and diabetes drugs with strong, growing demand
- Price fell hard recently; early signs buyers are stepping back in
- Recent negative headlines pushed shares down, creating a potential entry
- Court cases and healthcare budget limits could weigh on future growth
How it played out
NVO: rebound peaked below the target
Lyra published NVO at 54.38 on 2025-09-11, with 16% expected growth over the short term. The thesis pointed to weight-loss and diabetes drug demand, a recent price drop, signs that buyers may have been returning, and risks from court cases and healthcare budget limits.
Inside the window from 2025-09-11 to 2025-12-10, NVO rose to a peak of 62.32 on 2025-09-19, a 14.6% gain. It stayed below the 63.08 target. It ended at 49.05. The thesis partly played out: the rebound came quickly, but it never got there and did not hold.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.